Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




HPV Testing Offers Women Longer Protection than Smear Testing

By Labmedica staff writers
Posted on 21 May 2008
Testing for human papillomavirus (HPV) can be twice as effective at protecting women from developing cervical abnormalities as smear testing.

Nearly 3000 women aged 35+ were recruited into a study between April 1994 and September 1997. More...
They were asked to participate in the study in which HPV testing would be performed in addition to cytology (smear test) whilst attending their general practitioner (GP) practice (40 practices were involved in the trial) for a routine cervical smear.

All women tested were followed up passively using data from the national computerized system that records all smears and their results--the Open-Exeter system. Women with a smear history indicating the need for colposcopy--a more thorough examination of the cervix--were investigated further to determine whether the colposcopy and biopsy were performed, and what the resultant outcome was. Passive follow-up was complete for all women by early 2005.

Results showed that the risk of developing cervical abnormalities at one, five, and nine years after a normal smear test was 0.33%, 0.83%, and 2.20% respectively, with those odds significantly reduced after a negative HPV test--0.19%, 0.42%, and 1.88%, respectively.

The study was led by Prof. Jack Cuzick of Barts and The London School of Medicine and Dentistry (London, UK) and the results were published on May 15, 2008, in the International Journal of Cancer.

Prof. Cuzick said that HPV testing "offers women excellent protection from cervical abnormalities for at least six years after a negative test, compared to protection from a normal smear test which begins to wane after about three years. This suggests that the screening interval can be safely extended to at least six years with HPV testing. These data provide more support for replacing screening based on abnormal cells, with a more sensitive test based on screening for the human papillomavirus.”


Related Links:
Barts and The London School of Medicine and Dentistry

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.